BioSpace News Archive

Recordati Announces US NDA Approval of Isturisa® (osilodrostat), the First and Only FDA Approved Cortisol Synthesis Inhibitor for Patients with Cushing’s Disease. Company Builds Endocrinology Business Unit in the U.S.

Medtronic plc, the global leader in medical technology, announced it will participate in the virtual Barclays Global Healthcare Conference on Wednesday, March 11, 2020.

Mend Urgent Care and Mend Medical –a Los Angeles-based chain of Urgent Care and Primary Care Centers—announced it will launch in-clinic and at-home coronavirus testing in response to the 2019 Novel Coronavirus outbreak.

Healthcare quality management aims to improve the effectiveness of treatments and increase the satisfaction of the patients with the services they are being provided with. For this purpose, various laws have been enacted by the governments all across the world so that the interests of the patients are protected.

Hoffer Plastics announced that the company has received the MedAccred certification, a medical device industry-managed supply-chain oversight program of the Performance Review Institute.

Northwest Kidney Centers has conferred its highest honor, the Clyde Shields Distinguished Service Award, on Joyce F. Jackson, its president and CEO for 21 years..

XACT Robotics™ today announced that it has been named by FierceMedTech as one of 2019’s class of Fierce 15, designating it as one of the most promising private medtech companies in the industry.

The Nashville Health Care Council announced the launch of Health Career Connect, an online job forum designed to connect health care employers and non-clinical talent.

Blueprint Medicines Corporation (NASDAQ: BPMC), today reaffirmed previously announced plans to host a live conference call and webcast on Monday, March 16, 2020 to report updated data from Part 1 of the Phase 2 PIONEER trial of avapritinib in patients with indolent systemic mastocytosis, following the cancellation of the 2020 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.

BioVentrix, Inc., developer of the first hybrid transcatheter device for left ventricular remodeling after a heart attack, today announced that it has been named by FierceMedTech as one of the “Fierce 15” for 2019, designating it as one of the most promising private medtech companies in the industry.